Two weeks ago, I wrote to tell you that, just halfway through the month of April, pot stock investors were benefitting from several powerful profit catalysts.
Any one of these would be great news for the sector, but there were three in play, all working to power weed stocks higher.
To be honest, things were looking so good, I didn't think the action could get much better...
But it sure did.
As if on cue, here in the last half of the month, some exciting, bullish new developments have come together to bring us even bigger gains.
U.S. Pot Stocks Are Set to Enjoy a Renewed "Trump Bump"
Now that California's mammoth $3.75 billion legal weed market is up and running, most of the cannabis cognoscenti have been watching Canada.
And for good reason.
This summer, Canada will become the first North American nation to fully legalize marijuana, even for recreational purposes. That's expected to add $5 billion in yearly sales to that nation's already big medical marijuana industry.
RELATED: Top five tiny Canadian pot stocks are set to skyrocket. Click here...
Even without recreational marijuana in Canada or California, North American legal marijuana sales soared 33% last year, to $9.7 billion. And marijuana research firm ArcView expects that trend to continue at a compound annual growth rate of 28% through 2021, when there could be $25 billion or more in North American sales.
But now, that attention is swinging back in America's direction.
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
That's because, on April 13, we learned that U.S. President Donald Trump and U.S. Sen. Cory Gardner (R-CO) have come to an agreement to end federal-level crackdowns on marijuana in states that have legalized it.
Gardner, whose state is a legal marijuana pioneer, says he sat down with Trump for a conversation about the state of the federal government's approach to legal cannabis.
The senator had been miffed since early January, when U.S. Attorney General Jeff Sessions, a marijuana dinosaur, rescinded a portion of the Cole Memo, the executive branch-level ruling that had shielded legalized states from federal scrutiny. Sessions' move left federal prosecutors free to once again go after cannabis operations in legalized states.
In response, Gardner started refusing to allow U.S. Department of Justice nominees to pass through the U.S. Senate.
But Gardner's agreement with Trump changes all that.
Gardner says the president has agreed to support federal legislation to allow states to regulate cannabis without fear of federal interference - and the White House has confirmed that. In return, Gardner will now allow Justice's nominees to go through again.
Pot stocks responded immediately...
The bellwether Horizons Medical Marijuana Life Sciences ETF (TSE: HMMJ) rose 9.2% from its low on April 13 following Gardner's statement - and is still 4.6% higher as of this writing.
My paid-up Nova-X Report readers who are following along with our Roadmap to Marijuana Millions weed recommendations cleaned up, too. Several of those picks responded immediately, with peak gains of 52.5%, 26.5%, and 9% in the aftermath. They're still up comfortably in the mid double-digits.
FORGET JEFF SESSIONS: There's nothing he can do to stop these $5 shares from taking off. Details...
As I've said, the embrace of legal cannabis from major public figures, like former U.S. House Speaker John Boehner, is big for the industry.
That's because institutional investors, hedge funds, money managers, and other mainstream big-money players need that stability before they can jump in on this opportunity to tap a brand-new marketplace.
They realize that, despite legalized cannabis in dozens of states, it's still federally prohibited. The situation brings in a level of uncertainty to business operations that dampens enthusiasm.
But that's changing - quickly...
Red, White, and Blue and Green All Over
Just take a look at what's happened since news of the Gardner-Trump agreement surfaced.
Trump ally and longtime marijuana legalization proponent U.S. Rep. Dana Rohrabacher (R-CA) introduced a new bill - the Cannabis States' Rights Act - that he says would enshrine "restraint on federal enforcement." The bill would also loosen restrictions on conducting scientific research into the medicinal effects of cannabis; I can't overstate the importance of such a step for not only legal cannabis, but biotech, as well.
Rohrabacher's bill would make acts like producing, possessing, dispensing, and delivering cannabis under state cannabis laws also legal under federal law.
"Now there should be no question in Attorney General Sessions' mind about the president's intention," Rohrabacher said in a statement. "This is a fundamental issue of federalism and freedom, as state after state moves to take marijuana out of the hands of the cartels and place it in a competitive market where consumers can be assured of product safety."
Meanwhile, U.S. Senate Majority Leader Mitch McConnell (R-KY) fast-tracked a Senate bill to legalize industrial hemp - medical cannabis' low-THC-level cousin. And U.S. Senate Minority Leader Chuck Schumer (D-NY) says he's going to introduce a bill to entirely "de-schedule" marijuana from its federally prohibited status.
At the state level, a California measure introduced by state Sen. Robert Hertzberg (D-Van Nuys) to license special banks to handle the billions generated by legal cannabis companies gained steam after Trump's statement. Currently, federal prohibition substantially limits banking for these businesses.
Now, these are all great ideas. And happily for us, federal marijuana reform is one of few areas in 2018 where folks on both sides of the aisle work together; these efforts enjoy broad bipartisan support.
Nevertheless, getting anything passed in this Congress is going to be a challenge.
But... a flipped U.S. House of Representatives later this year could turn things around.
If that happens, the investment floodgates are going to open up.
When Canada Takes Weed Fully Legal...
It'll probably make our retrograde attorney general hopping mad, but there's really nothing on Earth he can do to stop these small cannabis companies from hitting the stratosphere. Sessions could be furious, but folks who park a few hundred dollars into these "north of the border" firms could potentially turn a small stake into $100,000 - and fast. Michael Robinson has the details for you - click here to hear what he's got to say...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.